A urine-based genomic test has demonstrated high accuracy in detecting bladder cancer across multiple NHS sites, according to a new prospective study led by the University of Birmingham and Nonacus Ltd.
The GALEAS Bladder test – which analyses DNA mutations across 23 genes associated with bladder cancer – detected 71 of 77 cancers (92.2%).
It identified all 17 muscle-invasive bladder cancers (100%) and 35 of 36 high-grade cancers (97.2%).
A negative result was associated with a 99.3% probability of not having bladder cancer.
For the 30% of patients with non-visible haematuria, GALEAS Bladder identified all bladder cancers (100%), with a negative result associated with a 100% probability of not having bladder cancer.
A urine-based genomic test has demonstrated high accuracy in detecting bladder cancer across multiple NHS sites, according to a new prospective study led by the University of Birmingham and Nonacus Ltd.
The study enrolled 964 patients referred for urgent haematuria investigation across seven NHS urology departments. The GALEAS Bladder test – which analyses DNA mutations across 23 genes associated with bladder cancer – detected 71 of 77 cancers (92.2%). It identified all 17 muscle-invasive bladder cancers (100%) and 35 of 36 high-grade cancers (97.2%). A negative result was associated with a 99.3% probability of not having bladder cancer.
For the 30% of patients with non-visible haematuria, GALEAS Bladder identified all bladder cancers (100%), with a negative result associated with a 100% probability of not having bladder cancer.
